Board of Directors
Bob co-founded Valleylab, Inc., in 1969. He served as CEO and Chairman
until January 1986, when he relinquished his role as CEO and continued as Chairman
until retiring in May 1996. The company, which focuses on electrosurgical and
ultrasonics systems, was acquired by Pfizer, Inc., in 1983.
Bob was named the first Boulder Entrepreneur of the Year in 1985. He
is currently a director of four medically-related companies.
In 1999, he received the "Pioneer in Endoscopy" award from the Society
of American Gastrointestinal Surgeons, for his early work in "keyhole" surgery.
He received the Outstanding Achievement Award from the University of Minnesota
in June 1992. Bob holds a bachelor's degree in Electrical Engineering
from the University of Minnesota (1963).
Ryan joined New Enterprise Associates (NEA) in 1996 as a Principal, became a Partner in 2002, and a General
Partner in 2004. He specializes in healthcare investments in the specialty
pharma, medical device and healthcare services sectors. Present board memberships
include BENU, Concentric Medical, Esprit Pharma, ExploraMed II, ForHealth
Technologies, FoxHollow Technologies (NASDAQ: FOXH), Intrinsic Therapeutics,
PatientKeeper, Provation Medical, Spine Wave, Viacor and Windward Medical.
Past board memberships include ESP Pharma (acquired by Protein Design Labs, Inc.)
and Proxima Therapeutics (acquired by Cytyc Corporation), and Ryan co-led NEA's investment in Xcel Pharmaceuticals (acquired by Valeant Pharmaceuticals, Inc.).
Prior to joining NEA, Ryan was with the Health Care Investment Banking Group
of Alex. Brown & Sons in San Francisco where he focused primarily on the
medical device, biopharmaceutical and healthcare services areas. Previously,
he worked in the San Francisco office of Arthur Andersen & Co. Ryan received
a BA from Stanford University.
Bob joined NEA in February 2005 as a venture partner evaluating new healthcare deals and working with existing NEA healthcare portfolio companies. Bob comes to NEA after a 36-year career at Johnson & Johnson where he held a series of senior positions, culminating with 12 years as Company Group Chairman.
Previously, he was Worldwide Franchise Chairman of Cordis, a Johnson & Johnson company. Prior to that, he was Worldwide Franchise Chairman for Ethicon Endo-Surgery. Bob began his career with Johnson & Johnson in 1968 as a Sales Representative for Ortho Pharmaceuticals, where he was named Vice President of Marketing. In 1985, Bob moved to McNeil Pharmaceutical as Vice President of Business Development and later transferred to Ethicon, Inc. as Group Vice President, where he remained until he was named President in 1990. In 1992 he was promoted to Worldwide President, Ethicon Endo-Surgery.
Bob is a graduate of Central Missouri State University, where he earned undergraduate and graduate degrees.
William M. Facteau
Bill joined EarLens Corporation as Chairman, President & CEO in November of 2013. He also serves on the Board of Directors of ExploraMed Development LLC, NeoTract, Inc., and Autonomic Technologies, Inc. (ATI). Bill was formerly the Chairman of the Board for Cabochon Aesthetics which was acquired in 2014 by Ulthera as well as an independent board member at CV Ingenuity (CVI), Inc., which was acquired by Covidien in 2013.
Previous to this, Bill was at Johnson and Johnson (JNJ) from January 2010 through January 2012 as Worldwide President of their ENT Division. Bill joined JNJ via the $800M acquisition of Acclarent, Inc. where he served as the President, CEO, and a member of the Board of Directors since the company’s formation in 2004. Under Bill’s leadership, the company went from concept to acquisition in 5 ½ years, raised over $100M, created jobs for approximately 400 employees, grew revenues to $100M and became profitable.
Prior to joining Acclarent, Bill was the General Manager of the Endovascular Division at Abbott Vascular, where he served as a member of the executive team and created the entry strategy for Abbott to participate in the peripheral vascular space. Bill joined Abbott Laboratories via the $683 million acquisition of Perclose, a vessel closure company, where he was Sales Director. From July 1993 to April 1998, Bill worked in a number of sales and sales management positions at United States Surgical Corporation. Bill received his B.A. in Political Science from the University of Connecticut, and is a named inventor on several issued patents.
Joshua Makower, M.D.
Josh is the Founder & Chief Executive Officer of ExploraMed II, Inc., a medical device incubator based on the west coast and is also a Venture Partner with New Enterprise Associates. Josh serves as a Consulting Professor of Medicine at Stanford University Medical School and is Co-Founder of Stanford’s Biodesign Innovation Program.
Prior to this, he was Founder, Chairman and Chief Technical Officer of TransVascular, Inc. a company focused on the development of a completely catheter-based coronary bypass technology, which was acquired by Medtronic, Inc. in 2003, and Founder and Chairman of EndoMatrix, Inc., a company focused on the development of a novel therapy for incontinence and GI Reflux, which was acquired by C.R. Bard in 1997. Up until 1995, Josh was Founder and Manager of Pfizer’s Strategic Innovation Group, a group chartered to create new medical device technologies and businesses for Pfizer’s medical devices businesses.
Josh holds over 200 patents for various medical devices in the fields of Cardiology, General Surgery, Drug Delivery and Urology. Dr. Makower holds a Masters of Business Administration degree from Columbia University, a Doctor of Medicine degree from the New York University School of Medicine, and a Bachelor of Science degree in Mechanical Engineering from the Massachusetts Institute of Technology.
Josh also serves serves as Chairman of the Boards for ExploraMed, Nuelle, Moximed, and NeoTract, and is a member of the board of directors for Ceterix, Coravin, and Intrinsic Therapeutics.